Colorectal cancer (CRC) is one the greatest contributors to cancer related mortality.
Although 5 year survival rate for patients at the early stage of CRC (stages I and II) is above …

BACKGROUND:: Fluorouracil (FU) is an antimetabolite with activity against numerous types
of neoplasms, including those of the breast, esophagus, larynx, and gastrointestinal and …

Mucinous ovarian cancer (MOC) is a rare subtype of epithelial ovarian carcinoma (EOC).
Whereas all EOC subtypes are addressed in the same way, MOC is a distinct entity …

Background The optimum use of cytotoxic drugs for advanced colorectal cancer has not
been defined. Our aim was to investigate whether combination treatment is better than …

Purpose: In North America, no effective therapy has been available for patients with
progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus …

Purpose Capecitabine has demonstrated high efficacy as first-line treatment for metastatic
colorectal cancer (MCRC). Oxaliplatin shows synergy with fluorouracil (FU), with little toxicity …

Background In many patients with advanced synchronous liver metastases from colorectal
tumours, the metastases progress during treatment of the primary, precluding curative …

Oncology is one of the few areas of medicine where most patients are treated intravenously
rather than receiving oral drugs. Recently, several oral anti-cancer drugs have been …

Combination chemotherapy regimens including irinotecan and oxaliplatin markedly improve
response rate and prolong median survival over fluorouracil with leucovorin (FU/LV), and …

Background Oral capecitabine achieves a superior response rate with an improved safety
profile compared with bolus 5-fluorouracil–leucovorin (5-FU/LV) as first-line treatment for …